Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

J&J hit with $21.7 million verdict in another talc asbestos cancer case

Published 05/23/2018, 07:17 PM
Updated 05/23/2018, 07:20 PM
© Reuters. FILE PHOTO:  A Johnson & Johnson building is shown in Irvine, California

By Tina Bellon

NEW YORK (Reuters) - Johnson & Johnson (N:JNJ) and its talc suppliers on Wednesday were hit with a $21.7 million jury verdict in a lawsuit by a woman who said she developed cancer after being exposed to asbestos in the company's Baby Powder.

The verdict by a Los Angeles jury came down in the case of 68-year-old Joanne Anderson, who was diagnosed with mesothelioma, a form of cancer closely linked to asbestos exposure, and marked the second trial loss for J&J over similar allegations.

Of the $21.7 million the jury awarded in compensatory damages, J&J was assigned 67 percent, with the rest distributed among other defendants.

J&J has vehemently denied that its talc products contain asbestos or cause cancer, citing decades of testing by independent laboratories and scientists. But plaintiffs claim that asbestos and talc, which are closely linked minerals, are intermingled in the mining process, making it impossible to remove the carcinogenic substance.

Anderson and her husband in 2017 had sued J&J, a unit of Imerys SA (PA:IMTP), Cyprus Amax Minerals, a unit of Brenntag (DE:BNRGn), Honeywell International (N:HON) and other local talc suppliers, but it was not immediately clear which of those companies were subject to the remaining damages award.

Damages could still grow as the jury debates whether to award punitive damages, Anderson's lawyer, Chris Panatier, said, declining to comment further.

"While we are disappointed with this decision, the jury has further deliberations to conduct in this trial and we will reserve additional comment until the case is fully completed," J&J said in a statement.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

J&J has also been battling some 6,000 cases claiming its baby powder caused ovarian cancer, but the talc litigation has taken a new focus in recent months with plaintiffs claiming the widely used product causes mesothelioma due to alleged asbestos contamination.

Wednesday's verdict marks the second trial loss for J&J over allegations that its talc-based products contain asbestos.

A New Jersey state court jury in April ordered J&J and its talc supplier, a unit of Imerys SA (PA:IMTP), to pay $117 million to a man who alleged he developed mesothelioma due to asbestos exposure from J&J Baby Powder. An appeal is pending.

A California jury in November last year cleared J&J of liability in another mesothelioma lawsuit.

The company and Imerys, as well as a local unit of U.S. drugstore chain Rite Aid (N:RAD), are also facing another mesothelioma trial in a South Carolina court.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.